ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
FDA has imposed an import alert related to Wockhardt, a leading Indian manufacturer of generic drugs. The action bans from the U.S. all but five of the pharmaceuticals that the company makes at its Chikalthana site. In May, FDA had imposed an alert on products from another Wockhardt plant in India. The bans were imposed because of unspecified failures by the firm to comply with drug manufacturing standards, according to FDA. Wockhardt says it is working to resolve the problems.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X